AlloSource®, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, has been granted a patent for an acellular human dermal matrix processed to be delivered via syringe. U.S. Patent Number 9,162,011, titled Flowable matrix compositions and methods, reinforces the company's commitment to wound care solutions.
The subject of this new patent is an allograft that can be injected or molded by hand for placement in hard-to-reach wounds. Current solutions in AlloSource's wound care portfolio include AlloSkin™ AC Acellular Dermal Matrix (ADM) and AlloSkin™, which is available in both cryopreserved and room temperature storage options.
"A new delivery system is a great example of our ongoing commitment to providing advanced solutions for our healthcare partners," said Thomas Cycyota, AlloSource president and CEO. "We are motivated by the challenge to help heal patients through new uses for donated tissue."
By focusing on quality, safety, service and a commitment to its mission, AlloSource has grown into one of the nations' largest tissue networks in the country. The company's safety and tissue processing standards meet and exceed guidelines set forth by the United States Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB).
U-M study reveals potential pathway to reverse lung fibrosis